Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Astra_Zeneca
|
| gptkbp:awards |
Best Workplaces in Canada
|
| gptkbp:benefits |
Comprehensive employee benefits
|
| gptkbp:clinical_trial |
Conducts clinical research trials
Focus on patient-centric research Conducts clinical trials in Canada Generates clinical data for research |
| gptkbp:collaborations |
Academic institutions
Collaborates with research institutions |
| gptkbp:community_health |
Contributes to public health initiatives
|
| gptkbp:community_involvement |
Health initiatives
|
| gptkbp:community_partnerships |
Works with NGOs for health projects
|
| gptkbp:community_support |
Supports local communities
|
| gptkbp:cultural_diversity |
Promotes diversity and inclusion
|
| gptkbp:employees |
Approximately 1,000
|
| gptkbp:focus_area |
gptkb:Research_and_Development
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:funding |
Provides research funding opportunities
|
| gptkbp:global_presence |
Part of global Astra Zeneca network
|
| gptkbp:headquarters |
gptkb:Mississauga,_Ontario
|
| gptkbp:health_innovation |
Supports health innovation initiatives
|
| gptkbp:health_partnerships |
Collaborates with health authorities
|
| gptkbp:healthcare |
Engages with healthcare professionals
Improves access to healthcare |
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca Canada
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Promotes innovation in healthcare
|
| gptkbp:instruction_set |
Diverse product pipeline
|
| gptkbp:investment_in_r&_d |
Significant investment in R& D
|
| gptkbp:leadership |
CEO is David Fredrickson
|
| gptkbp:market_position |
Strong presence in Canadian market
|
| gptkbp:marketing_strategy |
Patient-focused market strategy
|
| gptkbp:operates_in |
gptkb:Canada
|
| gptkbp:parent_company |
gptkb:Astra_Zeneca_PLC
|
| gptkbp:partnerships |
Various healthcare organizations
|
| gptkbp:patient_education |
Provides patient education resources
|
| gptkbp:products |
gptkb:vaccine
Oncology drugs Cardiovascular drugs Respiratory drugs |
| gptkbp:provides_guidance_on |
Follows clinical guidelines
|
| gptkbp:regulatory_compliance |
gptkb:Health_Canada
Complies with regulatory standards |
| gptkbp:research_areas |
Multiple therapeutic areas
|
| gptkbp:research_focus |
Innovative medicines
|
| gptkbp:safety |
Prioritizes patient safety
|
| gptkbp:safety_measures |
High safety standards in drug development
|
| gptkbp:social_responsibility |
Active CSR initiatives
|
| gptkbp:subsidiary |
gptkb:Astra_Zeneca_PLC
|
| gptkbp:sustainability_initiatives |
Environmental responsibility programs
|
| gptkbp:training |
Continuous professional development
|
| gptkbp:treatment |
Focus on improving health outcomes
Focus on improving clinical outcomes |
| gptkbp:type_of_care |
Engages with patients
|
| gptkbp:user_engagement |
High employee engagement levels
|
| gptkbp:website |
www.astrazeneca.ca
|
| gptkbp:bfsParent |
gptkb:Bell_Canada
|
| gptkbp:bfsLayer |
5
|